Zalutumumab in head and neck cancer
| Autor: | T.M. Richards, Christopher M. Nutting, Ulrike Schick, Kevin J. Harrington, Dorothy M. Gujral |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Drug medicine.medical_specialty media_common.quotation_subject medicine.medical_treatment Clinical Biochemistry Antibodies Monoclonal Humanized Medical Oncology Models Biological Disease-Free Survival Targeted therapy Zalutumumab Mice Internal medicine Drug Discovery medicine Animals Humans Stage (cooking) Adverse effect Randomized Controlled Trials as Topic media_common Pharmacology Clinical Trials as Topic business.industry Head and neck cancer Antibodies Monoclonal medicine.disease Rash ErbB Receptors Treatment Outcome Head and Neck Neoplasms Toxicity Carcinoma Squamous Cell medicine.symptom business medicine.drug |
| Zdroj: | Expert Opinion on Biological Therapy. 12:119-125 |
| ISSN: | 1744-7682 1471-2598 |
| DOI: | 10.1517/14712598.2012.643864 |
| Popis: | Over 90% of head and neck cancers overexpress EGFR. This correlates with advanced disease stage and worse prognosis. Strategies to inhibit the EGFR pathway have been developed over the last decade. Zalutumumab is a recent high-affinity completely human IgG1k antibody targeting EGFR.The mechanism of action and data on efficacy and safety of zalutumumab in head and neck cancer.Zalutumumab has demonstrated acceptable toxicity in head and neck cancer patients, with rash being the most common adverse event. The toxicity profile makes zalutumumab an attractive option for patients who are heavily pretreated and/or have poor performance status due to concurrent co-morbidities. As the molecule is fully human, the likelihood of hypersensitivity to the drug is low. Zalutumumab may be effective at low concentrations through antibody-dependent cellular cytotoxicity. Current data from Phase I and II trials identify zalutumumab as a promising drug for the treatment of locally advanced head and neck cancer and recent data from a Phase III randomized trial showed encouraging survival results compared with best supportive care. Results from other ongoing Phase III trials will provide clarification on zalutumumab as a treatment option. The clinical development of this compound has been suspended from June 2011 until a development and commercialization partner is found. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|